ATE364374T1 - Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit - Google Patents

Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

Info

Publication number
ATE364374T1
ATE364374T1 AT98305960T AT98305960T ATE364374T1 AT E364374 T1 ATE364374 T1 AT E364374T1 AT 98305960 T AT98305960 T AT 98305960T AT 98305960 T AT98305960 T AT 98305960T AT E364374 T1 ATE364374 T1 AT E364374T1
Authority
AT
Austria
Prior art keywords
solid pharmaceutical
increased bioavailability
pharmaceutical dispersions
dispersions
biavailability
Prior art date
Application number
AT98305960T
Other languages
English (en)
Inventor
William John Curatolo
Scott Max Herbig
James Alan Schrive Nightingale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21996463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE364374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE364374T1 publication Critical patent/ATE364374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J8/00—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes
    • B01J8/005—Separating solid material from the gas/liquid stream

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98305960T 1997-08-11 1998-07-27 Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit ATE364374T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5522197P 1997-08-11 1997-08-11

Publications (1)

Publication Number Publication Date
ATE364374T1 true ATE364374T1 (de) 2007-07-15

Family

ID=21996463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98305960T ATE364374T1 (de) 1997-08-11 1998-07-27 Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

Country Status (14)

Country Link
US (7) US8263128B2 (de)
EP (1) EP0901786B1 (de)
JP (1) JP2984661B2 (de)
CN (3) CN1207896A (de)
AT (1) ATE364374T1 (de)
BR (1) BR9803144A (de)
CA (1) CA2245269C (de)
CY (1) CY1107726T1 (de)
DE (1) DE69837903T2 (de)
DK (1) DK0901786T3 (de)
ES (1) ES2287971T3 (de)
IL (1) IL125627A (de)
PT (1) PT901786E (de)
TW (1) TWI230079B (de)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1027885B1 (de) * 1999-02-09 2008-07-09 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
PT1088824E (pt) * 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
PT1242055E (pt) * 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
EP2415462A1 (de) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Verbesserte pharmazeutische Zusammensetzungen für schwerlösliche Arzneistoffe
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
EP1345589B1 (de) * 2000-11-29 2007-06-27 Lyotropic Therapeutics, Inc. Lösungsmittelsysteme für pharmazeutische mittel
US6904706B2 (en) * 2001-04-24 2005-06-14 U Turn Sports Co., Llc Mo Llc. Sandal, thong or the like with reversible tongue, vamp, or strap
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
CZ20033456A3 (en) 2001-06-22 2004-07-14 Pfizer Products Inc. Pharmaceutical compositions comprising adsorbates of amorphous drug
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
DE60220049T2 (de) 2001-06-22 2007-08-30 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
PL368587A1 (en) 2001-06-22 2005-04-04 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007433A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (de) 2002-02-01 2017-08-23 Bend Research, Inc Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
MY135609A (en) * 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
JP2004339162A (ja) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
MXPA06005489A (es) * 2003-11-14 2006-08-11 Pfizer Prod Inc Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad.
JP2007514758A (ja) * 2003-12-19 2007-06-07 シェーリング　コーポレイション 医薬組成物
CA2555133A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
CA2568007A1 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
JP2008511609A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
KR20070046892A (ko) 2004-08-31 2007-05-03 화이자 프로덕츠 인크. 저용해도 약물 및 중합체를 포함하는 제약 투여형
US20080096924A1 (en) * 2004-12-17 2008-04-24 Ono Pharmaceutical Co., Ltd. Amorphous Composition
RU2007123436A (ru) * 2004-12-20 2009-01-27 Др. Редди` Лабораторис Лтд. (IN) Фармацевтическая композиция, содержащая аморфные соединения бензимидазола, и способ ее приготовления
US9265731B2 (en) 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP1871346A4 (de) * 2005-04-20 2012-07-18 Ctc Bio Inc Pharmazeutische zusammensetzung mit freier base aus sibutramin und herstellungsverfahren dafür
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP1906926B1 (de) * 2005-07-28 2010-12-01 Otsuka Pharmaceutical Co., Ltd. Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolderivaten
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
KR20080033383A (ko) * 2005-08-12 2008-04-16 아스트라제네카 아베 방법
JP5026426B2 (ja) * 2005-08-29 2012-09-12 サノフイ−アベンテイス・ユー・エス・エルエルシー ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドのアモルファス固体分散体
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
LT1993360T (lt) * 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
EA018811B1 (ru) * 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
NZ596889A (en) 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US20090062538A1 (en) * 2007-09-05 2009-03-05 Surya Narayana Devarakonda Amorphous valganciclovir hydrochloride
JPWO2009038112A1 (ja) * 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
HRP20191104T1 (hr) * 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
EP2291079B1 (de) 2008-05-14 2013-04-24 Merck Sharp & Dohme Corp. Formulierungen für cathepsin-k-hemmer
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
US8685458B2 (en) 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN102666553B (zh) 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
US20120225900A1 (en) 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SMT202100051T1 (it) * 2010-03-25 2021-03-15 Vertex Pharma Dispersione solida di una forma amorfa di (r)-1-(2,2-difluorobenzo[d][1,3]diossol-5-il)-n-(1-(2,3-diidrossipropil)-6-fluoro-2-(1-idrossi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropan-carbossamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
EP2571860A1 (de) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl-benzoylamide
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
BR112012031516A2 (pt) 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
KR101807338B1 (ko) 2010-06-14 2018-01-10 다우 글로벌 테크놀로지스 엘엘씨 아세테이트 및 석신에이트 치환이 향상된 하이드록시프로필 메틸 셀룰로즈 아세테이트 석신에이트
ES2676209T3 (es) * 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
PT2632925E (pt) 2010-10-29 2015-09-01 Pfizer Inibidores de n1/n2-lactama da acetil-coa carboxilase
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
RS54526B1 (sr) 2011-04-22 2016-06-30 Pfizer Inc. Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
WO2013117671A1 (fr) * 2012-02-07 2013-08-15 Centre National De La Recherche Scientifique (C.N.R.S) Préparation de nanoparticules par évaporation flash
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
PE20142164A1 (es) 2012-04-06 2014-12-27 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
PT2874607T (pt) * 2012-07-17 2017-08-14 Dow Global Technologies Llc Resumo
KR102138545B1 (ko) * 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 고분자량 및 높은 균일성을 갖는 신규한 에스테르화된 셀룰로즈 에테르
BR112015002055A2 (pt) * 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
CN104755503B (zh) * 2012-08-24 2018-03-06 陶氏环球技术有限责任公司 在脂族羧酸的存在下制备纤维素醚的酯的方法
BR112015005404A2 (pt) 2012-09-11 2017-08-22 Dr Reddys Laboratories Ltd Formas polimórficas de enzalutamida e sua preparação
EP4450130A3 (de) * 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Enzalutamidformulierungen
CA3053189A1 (en) * 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
EP3007689B1 (de) 2013-01-10 2018-03-07 Pulmokine, Inc. Nicht-selektive kinasehemmer
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9492550B2 (en) 2013-03-01 2016-11-15 Hercules Llc Pharmaceutical compositions with enhanced performance and improved processability
JP6334574B2 (ja) 2013-03-07 2018-05-30 ダウ グローバル テクノロジーズ エルエルシー 新規の超高分子量のエステル化セルロースエーテル
JP6267239B2 (ja) 2013-03-07 2018-01-24 ダウ グローバル テクノロジーズ エルエルシー 極めて低粘度の新規エステル化セルロースエーテル
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CN103242542B (zh) * 2013-05-29 2015-04-15 南京农业大学 非晶纤维素分散液的生产方法
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen
EP3054937B1 (de) 2013-10-11 2023-07-26 Pulmokine, Inc. Sprühtrocknungsformulierungen
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
MX384259B (es) * 2014-01-09 2025-03-14 Verastem Inc Composiciones y metodos para tratamiento de crecimiento celular anormal.
KR102163211B1 (ko) 2014-02-04 2020-10-08 내셔널 유니버시티 오브 싱가포르 금속 및 결정 기판 상에 펄스 레이저를 기초로 한 대면적 그래핀의 합성 방법
EP2913048A1 (de) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmazeitische Zusammensetzung enthaltend trametinib
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
EP3204358B1 (de) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Cokristalle von modulatoren des transmembrankonduktanzregulators bei zystischer fibrose
EP3209960A1 (de) 2014-10-23 2017-08-30 Bend Research, Inc. Sprühdüse und verfahren zur herstellung von nanopartikeln
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
RS66323B1 (sr) * 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
KR102055542B1 (ko) 2015-03-10 2019-12-13 시오노기 잉크 고체 분산체
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
MY191207A (en) 2015-07-29 2022-06-08 Nat Univ Singapore A method of protecting a magnetic layer of a magnetic recording medium
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
CN105223326B (zh) * 2015-09-23 2017-01-18 天津中医药大学 一种中药口服速释制剂中活性成分的体外分类方法
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
KR20250126877A (ko) 2015-10-15 2025-08-25 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
BR112018011154B1 (pt) * 2015-11-30 2023-09-26 Cyclerion Therapeutics, Inc Dispersões sólidas compreendendo um estimulador de sgc
CN109152742B (zh) * 2016-05-25 2021-05-04 陶氏环球技术有限责任公司 纤维素醚乙酸酯的水溶液
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
EP3939591A1 (de) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Chinazolin- und indolverbindungen zur behandlung von medizinischen leiden
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US20190209469A1 (en) 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
KR20230093341A (ko) 2016-10-27 2023-06-27 풀모킨 인코포레이티드 폐고혈압을 치료하기 위한 병용 요법
JP2020506790A (ja) * 2016-11-10 2020-03-05 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 界面活性剤及びその製造方法
US20200000710A1 (en) * 2017-02-01 2020-01-02 Zion Azar Systems Methods Devices Apparatuses Circuits and Computer Executable Code for Production and Topical Application of a Therapeutic Substance
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
KR102582626B1 (ko) 2017-03-10 2023-09-22 화이자 인코포레이티드 Lrrk2 억제제로서의 신규 이미다조[4,5-c]퀴놀린 유도체
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
EP3773509B1 (de) 2018-04-06 2023-11-01 Capsugel Belgium NV Sprühtrocknungsverfahren für teilchen mit niedrigem aspektverhältnis mit poly[(methyl-methacrylat)-co-(methacrylsäure)]
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
PE20211070A1 (es) 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
CN113166177B (zh) 2018-10-05 2024-09-03 辉瑞公司 含硼的pde4抑制剂
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
SG11202103861YA (en) * 2018-11-06 2021-05-28 Beijing Innocare Pharma Tech Co Ltd Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
WO2020122243A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 医薬組成物及びその製造方法
CA3132530A1 (en) 2019-04-11 2020-10-15 Robert J. GARMISE Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations
MX2021012491A (es) 2019-04-19 2022-01-24 Pfizer Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP4578460A3 (de) 2019-05-20 2025-08-27 Pfizer Inc. Kombinationen mit benzodioxol als glp-1r-agonisten zur verwendung bei der behandlung von nash/nafld und verwandten erkrankungen
EP3972569A1 (de) 2019-05-23 2022-03-30 Helm AG Nanopartikel mit enzalutamid
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP4013393B1 (de) 2019-08-15 2024-06-05 Capsugel Belgium NV Ammoniak als verarbeitungshilfsmittel für gesprühte feststoffdispersionen
US20220401425A1 (en) * 2019-08-28 2022-12-22 Shenzhen Chipscreen Biosciences Co., Ltd. Chidamide pharmaceutical composition, preparation method therefor and application thereof
CN119424434A (zh) * 2019-09-18 2025-02-14 百时美施贵宝公司 Tyk2抑制剂的剂型
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
US20230105108A1 (en) 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
CN111184692B (zh) * 2020-02-14 2021-10-26 南京大渊医美生物技术有限公司 一种白藜芦醇的制剂及其制备方法
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
WO2021188989A1 (en) * 2020-03-19 2021-09-23 Onza Corp. Gas-phase antimicrobial delivery via infused crystalline and porous solids
EP4652997A3 (de) 2020-05-19 2026-03-04 Pharmacosmos Holding A/s Cyclinabhängige kinasehemmende verbindungen zur behandlung von medizinischen erkrankungen
PT4161927T (pt) 2020-06-09 2024-10-08 Pfizer Compostos de espiro como antagonistas do recetor de melanocortina 4 e utilizações dos mesmos
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
TWI782599B (zh) 2020-07-02 2022-11-01 美商輝瑞股份有限公司 胺基嘧啶基衍生物
MX2023003194A (es) * 2020-09-18 2023-04-13 Bristol Myers Squibb Co Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
JP2023552863A (ja) 2020-12-15 2023-12-19 ファイザー・インク ベンゾイミダゾール誘導体および皮膚疾患の処置のためのｉｔｋの阻害剤としてのそれらの使用
EP4263538A1 (de) 2020-12-15 2023-10-25 Pfizer Inc. Pyrido[2,3-d!imidazolderivate und ihre verwendung als itk-hemmer zur behandlung von hauterkrankungen
AU2022270171B2 (en) 2021-05-07 2026-01-08 Gb002, Inc. Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
JP2024520798A (ja) * 2021-06-09 2024-05-24 ロンザ・ベンド・インコーポレーテッド 非晶質固体分散体の調製のための噴霧乾燥のための混合溶媒
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
MX2024006739A (es) 2021-12-01 2024-06-19 Pfizer Derivados de acido 3-fenil-1-benzotiofeno-2-carboxilico como inhibidores de alfa cetoacido deshidrogenasa quinasa de cadena ramificada para el tratamiento de diabetes, enfermedad renal, esteatohepatitis no alcoholica (nash) e insuficiencia cardiaca.
CA3241470A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
US20230402379A1 (en) * 2022-06-13 2023-12-14 International Business Machines Corporation Hybrid signal and power track for stacked transistors
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
EP4598908A1 (de) 2022-10-07 2025-08-13 Pfizer Inc. Hsd17b13-inhibitoren und/oder degrader
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
JP2025541231A (ja) 2022-12-16 2025-12-18 ファイザー・インク ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用
CN121358484A (zh) * 2023-04-18 2026-01-16 因西克利克斯生物有限责任公司 用于施用inx-315的有利的人类剂量方案
WO2025003905A1 (en) 2023-06-29 2025-01-02 Pfizer Inc. Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
JP2025015449A (ja) 2023-07-18 2025-01-30 信越化学工業株式会社 固体分散体用組成物、固体分散体及び固体分散体の製造方法
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN117298101A (zh) * 2023-11-17 2023-12-29 中国药科大学 提高spd1027药用盐型表观溶解度和生物利用度的药物组合物及其制备方法和应用
WO2026033474A1 (en) 2024-08-08 2026-02-12 Takeda Pharmaceutical Company Limited Deuterated compounds and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS57176907A (en) 1981-04-23 1982-10-30 Yamanouchi Pharmaceut Co Ltd Readily absorbable solid pharmaceutical composition of as-56c
GB2132495B (en) 1982-12-16 1986-09-24 Cpc International Inc Spray drying
JPS61227524A (ja) 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
JPH0215027A (ja) 1988-07-01 1990-01-18 Takada Seiyaku Kk 新規なプロブコール固形製剤
DE69022861T2 (de) 1989-01-24 1996-04-04 Spi Polyols Inc Kryoschützende kristalline Sorbitolkügelchen.
JPH0374396A (ja) 1989-08-16 1991-03-28 Mercian Corp 抗菌性組成物
EP0421581A1 (de) 1989-10-03 1991-04-10 Warner-Lambert Company Kaubare sprühgetrocknete spheroide Mikrokapseln, wachsüberzogene Mikrokapseln und Verfahren zu ihrer Herstellung
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
EP0421582A1 (de) 1989-10-03 1991-04-10 Warner-Lambert Company Kaubare sprühgetrocknete spheroide Mikrokapseln, polymerüberzogene Mikrokapseln und Verfahren zu ihrer Herstellung
EP0580860B2 (de) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Verfahren zur herstellung einer festen dispersion
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE69332105T2 (de) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
JP3469926B2 (ja) 1993-11-04 2003-11-25 太田製薬株式会社 大腸内放出型医薬製剤用粒状物
EP0748213B1 (de) * 1994-03-07 2004-04-14 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
DK0797987T3 (da) * 1994-12-19 2004-02-16 Daiichi Seiyaku Co Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
CA2222811C (en) * 1995-06-01 2008-09-30 G.D. Searle & Co. Stabilized solid dispersions of misoprostol
ES2199289T3 (es) 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2229285A1 (en) 1995-09-21 1997-03-27 Robert Gurny Nanoparticles in photodynamic therapy
ES2184063T3 (es) 1996-03-18 2003-04-01 Nissan Chemical Ind Ltd Procedimiento de produccion de preparaciones de clorhidrato de efonidipina.
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
AU3360197A (en) * 1996-07-01 1998-01-21 Universiteit Utrecht Hydrolysable hydrogels for controlled release
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (de) * 1996-11-19 1998-05-20 OctoPlus B.V. Mikrosphären zur gesteuerten Freisetzung und Verfahren zur Herstellung dieser Mikrosphären
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1745774A3 (de) 1997-08-11 2007-04-11 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
EP1027885B1 (de) 1999-02-09 2008-07-09 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
GB9927011D0 (en) * 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
MXPA02006079A (es) 1999-12-20 2004-08-23 Nicholas J Kerkhof Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
JP2006140084A (ja) * 2004-11-15 2006-06-01 Koito Mfg Co Ltd 車両用灯具

Also Published As

Publication number Publication date
PT901786E (pt) 2007-08-07
JPH11116502A (ja) 1999-04-27
CY1107726T1 (el) 2013-04-18
US20120288542A1 (en) 2012-11-15
CA2245269C (en) 2003-01-28
EP0901786A3 (de) 2000-01-19
DE69837903T2 (de) 2008-02-14
US8257741B2 (en) 2012-09-04
CN101450212A (zh) 2009-06-10
IL125627A (en) 2009-02-11
CN1981742A (zh) 2007-06-20
US8337899B2 (en) 2012-12-25
EP0901786A2 (de) 1999-03-17
US8263128B2 (en) 2012-09-11
BR9803144A (pt) 2000-01-11
CA2245269A1 (en) 1999-02-11
IL125627A0 (en) 1999-04-11
DK0901786T3 (da) 2007-10-08
CN1207896A (zh) 1999-02-17
JP2984661B2 (ja) 1999-11-29
US20120328679A1 (en) 2012-12-27
EP0901786B1 (de) 2007-06-13
US20130224301A1 (en) 2013-08-29
US20150024054A1 (en) 2015-01-22
US20120292797A1 (en) 2012-11-22
US20030219489A1 (en) 2003-11-27
DE69837903D1 (de) 2007-07-26
US8367118B2 (en) 2013-02-05
ES2287971T3 (es) 2007-12-16
US20020009494A1 (en) 2002-01-24
US8431159B2 (en) 2013-04-30
TWI230079B (en) 2005-04-01

Similar Documents

Publication Publication Date Title
ATE364374T1 (de) Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1745774A3 (de) Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DE60004052D1 (de) Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
ATE238812T1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
FI960042L (fi) Farmaseuttisia valmisteita niukkaliukoisia aktiivisia aineita varten
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS1950B (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
ATE109145T1 (de) Heterozyklische acylaminothiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DK1037667T3 (da) Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder
IS6082A (is) Sykursteraviðtakastillar ásamt notkun þar á og lyfjaefnablöndur
ATE243708T1 (de) Substituierte imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE59813619D1 (de) Ascorbinsäurederivate enthaltende kosmetische und pharmazeutische Zubereitungen
DE69815094D1 (de) 2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE69813602D1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
ATE449786T1 (de) Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE469644T1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
TR200002099A3 (tr) Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
DK1189637T3 (da) Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
DE60004815D1 (de) Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0901786

Country of ref document: EP